A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Inclusion Criteria : * Age of 18 years or greater. * Ambulatory. * In reasonably good health as assessed by the investigator. * Available for duration of the study (21 days + 2d). * Willing and able to meet protocol requirements. * Willing and able to give informed consent. Exclusion Criteria : * Self-reported allergy to egg proteins, chicken proteins, or one of the constituents of the vaccine, such as thimerosal or formaldehyde. * An acute illness with or without fever (temperature \>100.4°F) in the 72 hours preceding enrollment in the trial. * Clinically significant findings in vital signs (including temperature \>100.4°F) or review of systems. * Self-reported history of severe adverse event to any influenza vaccine. * Vaccination against influenza in the 6 months preceding enrollment in the study. * Any vaccination in the 14 days preceding enrollment in the study or scheduled between Visit 1 and Visit 3. * Participation in any other experimental drug or vaccine trial within the 30 days preceding enrollment into the study. * Immunosuppressive therapy including long-term (\> 2 weeks) systemic corticosteroids or cancer therapy within the past 3 months or ongoing. * Receipt of blood or blood products within the 3 months preceding enrollment in the study. * Diabetes * Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine (e.g., existing severe chronic illness such as pulmonary disorders, cardiovascular disorders, chronic blood disorders, etc.). * Person deprived of freedom by an administrative or court order (having legal or medical guardian). * For women of childbearing age, a positive urine pregnancy test, breast feeding, or not using a medically approved and reliable form of contraception (oral contraceptives or double barrier method) for the duration of the trial.